Shares of Charles River Laboratories International Inc. CRL slipped 1.33% to $163.64 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index ...

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts suggests these firms should brace for a similar R&D landscape in 2025.

Fifth Third Bancorp cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

BofA lowered the firm’s price target on Charles River (CRL) to $195 from $210 and keeps a Neutral rating on the shares. The firm updated its ...

Bank of America Securities analyst Juan Avendano reiterated a Hold rating on Charles River Labs (CRL – Research Report) today and set a price ...

Atomi Financial Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.